http://www.xconomy.com/san-diego/2009/04/07/moving-fast-trius-therapeutics-assesses-capital-needs-for-late-stage-clinical-trials/ Business + Technology in the Exponential Economy Sat, 11 Feb 2012 09:14:03 +0000 hourly 1 http://wordpress.org/?v=3.0.4 http://www.xconomy.com/san-diego/2009/04/07/moving-fast-trius-therapeutics-assesses-capital-needs-for-late-stage-clinical-trials/comment-page-1/#comment-52936 Venture Updates: Trius Therapeutics, Trophos, Mithridion | IguanaBio - A Daily Biotech and Pharma Tabloid - Gossip, News, Research, Humor and Updates on the Latest Events in Biotech and Pharma - Unique, Insightful, Truthful, Sometimes Sneaky Tue, 07 Apr 2009 15:40:37 +0000 http://www.xconomy.com/?p=19360#comment-52936 [...] We profiled Trius Therapeutics back in March 2008 when the antibiotic developer announced a $30M financing. Today, Xconomy is reporting that Trius has positive results from its Phase 2 clinical trial of TR-701, a second generation Linezolid, quoting a ” 96 percent cure rate.” Trius CEO Jeff Stein said the company plans to provide more detailed results of the trial in a few months. Trius is debating whether to raise an additional round or seek a partner. [Xconomy] [...] [...] We profiled Trius Therapeutics back in March 2008 when the antibiotic developer announced a $30M financing. Today, Xconomy is reporting that Trius has positive results from its Phase 2 clinical trial of TR-701, a second generation Linezolid, quoting a ” 96 percent cure rate.” Trius CEO Jeff Stein said the company plans to provide more detailed results of the trial in a few months. Trius is debating whether to raise an additional round or seek a partner. [Xconomy] [...]

]]>